199 related articles for article (PubMed ID: 12691136)
21. FLT3 mutations in myeloid sarcoma.
Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
23. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
[TBL] [Abstract][Full Text] [Related]
24. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA
Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Fröhling S; Schlenk RF; Breitruck J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K;
Blood; 2002 Dec; 100(13):4372-80. PubMed ID: 12393388
[TBL] [Abstract][Full Text] [Related]
26. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
27. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
Sheikhha MH; Awan A; Tobal K; Liu Yin JA
Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
30. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.
Abu-Duhier FM; Goodeve AC; Wilson GA; Gari MA; Peake IR; Rees DC; Vandenberghe EA; Winship PR; Reilly JT
Br J Haematol; 2000 Oct; 111(1):190-5. PubMed ID: 11091200
[TBL] [Abstract][Full Text] [Related]
31. FLT3: ITDoes matter in leukemia.
Levis M; Small D
Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
[TBL] [Abstract][Full Text] [Related]
32. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
33. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
35. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.
Zheng R; Klang K; Gorin NC; Small D
Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075
[TBL] [Abstract][Full Text] [Related]
36. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress.
Libura M; Asnafi V; Tu A; Delabesse E; Tigaud I; Cymbalista F; Bennaceur-Griscelli A; Villarese P; Solbu G; Hagemeijer A; Beldjord K; Hermine O; Macintyre E
Blood; 2003 Sep; 102(6):2198-204. PubMed ID: 12791658
[TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.
Chen W; Jones D; Medeiros LJ; Luthra R; Lin P
Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128
[TBL] [Abstract][Full Text] [Related]
38. AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication.
Takahashi S; Harigae H; Kameoka J; Sasaki T; Kaku M
Br J Haematol; 2005 Aug; 130(3):428-36. PubMed ID: 16042694
[TBL] [Abstract][Full Text] [Related]
39. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Bruserud Ø; Hovland R; Wergeland L; Huang TS; Gjertsen BT
Haematologica; 2003 Apr; 88(4):416-28. PubMed ID: 12681969
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
